The People’s Republic of China’s (PRC) National Development and Reform Commission has issud a “Consolidation Guidance”, on the 22nd of January 2013, aiming to accelerate consolidation within the pharmaceutical sector.
The goals, to be achieved by 2015, set out by the Consolidation Guidance are :
- Combined Sales Revenues from the top 100 pharmaceutical companies in China should account for more than half of the total PRC pharmaceutical sector sales revenue.
- The top 20 pharmaceutical companies in China, selling “Essential Pharmaceuticals”, which are mostly generic pharmaceuticals listed in the Essential Drugs list published by the MoH (Ministry of Health) and are subject to price regulations, should account for 80% of all “Essential Pharmaceutical” sales in China.
Source : www.mondaq.com Publication Date : 2013-02-28